GLP1R and type 2 diabetes mellitus: Farr and colleagues demonstrated the presence of GLP-1R in the hypothalamus, medulla, and parietal cortex through immunohistochemistry in human brain autopsies; then, in another randomized cohort of patients with type 2 diabetes, there was observed decreased fMRI activity in the parietal cortex, insula, and putamen after 17 days of treatment with liraglutide compared with placebo [80].